GleamWall
中文EN

PCSA Processa Pharmaceuticals, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1533743 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-1,393.5%
TTM EPS YoY34.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-203.8%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets1.0%
Debt / equity—
Current ratio97.70x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.07x
Accruals ratio-189.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$7.81M$7.27M
SG&A expense$6.18M$4.78M
Operating income-$13.99M-$12.05M
Pretax income-$13.56M-$11.85M
Net income-$13.56M-$11.85M
EBITDA-$13.99M-$12.05M
EPS (basic)-10.36-96.78
EPS (diluted)-10.36-96.78
Weighted avg. shares (diluted)1.31M122,438
Balance sheet
Cash & equivalents$5.54M$1.19M
Current assets$5.67M$1.88M
PP&E, net$4,000$5,016
Total assets$7.81M$3.23M
Current liabilities$2.24M$1.53M
Total liabilities$2.24M$1.53M
Shareholders' equity$5.58M$1.70M
Shares outstanding2.57M148,108
Cash flow statement
Operating cash flow-$11.39M-$11.25M
Capital expenditure—$3,244
Free cash flow—-$11.25M
Investing cash flow-$850,000-$3,244
Financing cash flow$16.58M$7.73M
Depreciation & amortization$1,204$782
Stock-based compensation$857,550$629,514

Free plan shows the latest 2 periods; Pro shows all 14 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.